2. Academic Validation
  3. Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology

Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology

  • J Antibiot (Tokyo). 2017 Nov 1. doi: 10.1038/ja.2017.138.
Hayamitsu Adachi 1,  Koichi Nakae 2,  Shuichi Sakamoto 1,  Chisato Nosaka 2,  Sonoko Atsumi 2,  Masabumi Shibuya 3,  Nobuaki Higashi 4,  Motowo Nakajima 5,  Tatsuro Irimura 6,  Yoshio Nishimura 2
Affiliations

Affiliations

  • 1 Institute of Microbial Chemistry (BIKAKEN), Numazu Branch, Shizuoka, Japan.
  • 2 Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
  • 3 Jobu University, Gunma, Japan.
  • 4 Hoshi University, Tokyo, Japan.
  • 5 SBI Pharmaceuticals Co., Ltd., Tokyo, Japan.
  • 6 Juntendo University School of Medicine, Tokyo, Japan.
PMID: 29089599 DOI: 10.1038/ja.2017.138
Abstract

Microbial metabolites have attracted increasing interest as a source of therapeutics and as probes for biological mechanisms. New microbial metabolites and derivatives targeted at inflammation and bone disease therapy have been identified by focusing on prostaglandin release, osteoblast differentiation and immune cell functions. These modulators of inflammatory processes and bone disease contribute to our understanding of biological mechanisms and support identification of the therapeutic potential of drug lead candidates. The present review describes recent advances in the chemistry and analysis of inhibitors of prostaglandin release or other Functional Molecules of immune cells, as well as inducers of osteoblast differentiation, including biological and pharmacological activities.The Journal of Antibiotics advance online publication, 1 November 2017; doi:10.1038/ja.2017.138.

Figures
Products